1. Home
  2. ARI vs SNDX Comparison

ARI vs SNDX Comparison

Compare ARI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARI
  • SNDX
  • Stock Information
  • Founded
  • ARI 2009
  • SNDX 2005
  • Country
  • ARI United States
  • SNDX United States
  • Employees
  • ARI N/A
  • SNDX N/A
  • Industry
  • ARI Real Estate Investment Trusts
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARI Real Estate
  • SNDX Health Care
  • Exchange
  • ARI Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • ARI 1.5B
  • SNDX 1.3B
  • IPO Year
  • ARI 2009
  • SNDX 2016
  • Fundamental
  • Price
  • ARI $10.23
  • SNDX $13.51
  • Analyst Decision
  • ARI Buy
  • SNDX Strong Buy
  • Analyst Count
  • ARI 4
  • SNDX 11
  • Target Price
  • ARI $10.67
  • SNDX $38.55
  • AVG Volume (30 Days)
  • ARI 858.1K
  • SNDX 3.1M
  • Earning Date
  • ARI 10-30-2025
  • SNDX 10-31-2025
  • Dividend Yield
  • ARI 9.73%
  • SNDX N/A
  • EPS Growth
  • ARI N/A
  • SNDX N/A
  • EPS
  • ARI N/A
  • SNDX N/A
  • Revenue
  • ARI $273,783,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • ARI $25.91
  • SNDX $641.22
  • Revenue Next Year
  • ARI $14.63
  • SNDX $110.64
  • P/E Ratio
  • ARI N/A
  • SNDX N/A
  • Revenue Growth
  • ARI 55.89
  • SNDX 2126.66
  • 52 Week Low
  • ARI $7.70
  • SNDX $8.58
  • 52 Week High
  • ARI $11.11
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • ARI 52.22
  • SNDX 34.29
  • Support Level
  • ARI $10.15
  • SNDX $13.03
  • Resistance Level
  • ARI $10.35
  • SNDX $15.79
  • Average True Range (ATR)
  • ARI 0.19
  • SNDX 1.04
  • MACD
  • ARI 0.04
  • SNDX -0.23
  • Stochastic Oscillator
  • ARI 79.99
  • SNDX 12.73

About ARI Apollo Commercial Real Estate Finance Inc

Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: